# Unveiling the role of interleukin-13 in liver fibrosis of chronic hepatitis B patients: Development of a predictive model

**Authors:** Muhammad Begawan Bestari, Muhammad Palar Wijaya, Dolvy Girawan, Nenny Agustanti, Eka Surya Nugraha, Xiaosheng Tan, Xiaosheng Tan, Xiaosheng Tan, Xiaosheng Tan

PMC · DOI: 10.1371/journal.pone.0344791 · PLOS One · 2026-03-23

## TL;DR

This study explores how interleukin-13 affects liver stiffness in chronic hepatitis B patients and creates a model to predict it.

## Contribution

The novel contribution is a predictive model for liver stiffness in CHB patients that includes interleukin-13 alongside age and platelet count.

## Key findings

- A predictive model with R2 of 0.37 was developed using age, platelet count, and IL-13 levels.
- Elevated IL-13 and lower platelet count are associated with increased liver stiffness.
- The model met statistical criteria for reliability and normal distribution.

## Abstract

Developing a non-invasive model is essential for assessing liver stiffness in conditions without transient elastography, which will determine further management in chronic hepatitis B (CHB) patients.

This study aims to evaluate the interleukin-13 role in liver fibrosis and develop a new predictive model that includes interleukin-13 and standard data such as age and platelet count.

Patients were recruited from Hasan Sadikin General Hospital’s CHB registry from October 2021 to January 2022. Patients underwent demographic data collection, complete blood count, interleukin-13, and transient elastography examinations on the same day. The platelet count variable was listed in ×109/ dL, and the interleukin-13 in pg/mL. Interleukin-13 values were categorized as positive for IL-13 with a cut-off of 5 pg/mL (ILcut5). The liver stiffness measurement was inverted to obtain a normal distribution and became inverseLSM as the model’s outcome. The prediction model was formed through multiple linear regression analysis.

The number of patients studied was 88. A prediction model for inverseLSM was formulated, had an R2 of 0.37, and consisted of age, platelet count, and ILcut5 with correlation coefficients of -0.221, 0.326, and −0.288, respectively. The model had no autocorrelation, multicollinearity, or significant outliers, a normal distribution appearance, and met the homoscedastic criterion. Elevated IL-13, decreased platelet count, and aging are linked to increased liver stiffness.

## Linked entities

- **Diseases:** chronic hepatitis B (MONDO:0005344)

## Full-text entities

- **Genes:** IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, CCL11 (C-C motif chemokine ligand 11) [NCBI Gene 6356] {aka SCYA11}, LGALS3BP (galectin 3 binding protein) [NCBI Gene 3959] {aka 90K, BTBD17B, CyCAP, M2BP, MAC-2-BP, TANGO10B}, CCN2 (cellular communication network factor 2) [NCBI Gene 1490] {aka CTGF, HCS24, IBP-8, IGFBP8, KMD, NOV2}, ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, GGTLC5P (gamma-glutamyltransferase light chain 5 pseudogene) [NCBI Gene 653590] {aka GGT}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}, IL13RA1 (interleukin 13 receptor subunit alpha 1) [NCBI Gene 3597] {aka CD213A1, CT19, IL-13Ra, NR4}, STAT6 (signal transducer and activator of transcription 6) [NCBI Gene 6778] {aka D12S1644, HIES6, IL-4-STAT, STAT6B, STAT6C}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, IL13RA2 (interleukin 13 receptor subunit alpha 2) [NCBI Gene 3598] {aka CD213A2, CT19, IL-13R, IL13BP}
- **Diseases:** chronic inflammation (MESH:D007249), hepatic steatosis (MESH:D005234), chronic kidney disease (MESH:D051436), pulmonary fibrosis (MESH:D011658), Liver Fibrosis (MESH:D008103), Hepatitis C (MESH:D019698), ORCID iD (MESH:C535742), LSM (MESH:D017093), pulmonary tuberculosis (MESH:D014397), chronic pancreatitis (MESH:D050500), CLD (MESH:D008107), stiffness (MESH:C566112), cancer (MESH:D009369), type 2 diabetes mellitus (MESH:D003924), Fibrosis (MESH:D005355), heart disease (MESH:D006331), TE (MESH:C563551), infection (MESH:D007239), hepatitis B (MESH:D006509), HIV (MESH:D015658), CHB (MESH:D019694)
- **Chemicals:** alcohol (MESH:D000438), bilirubin (MESH:D001663), PONE-D-25-42985R1 (-)
- **Species:** Hepatitis B virus (no rank) [taxon 10407], Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus 1 (no rank) [taxon 11676]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13008083/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13008083/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC13008083/full.md

---
Source: https://tomesphere.com/paper/PMC13008083